Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Hospitals Mount Campaign Against Site-Neutral Medicare Payments

(ModernHealthcare) Feb 26, 2015 - Hospital leaders are working to head off any momentum in Congress toward overhauling Medicare rates to pay hospitals the same for outpatient services as the program pays for the same services in physician offices.

Commentary: This report is somewhat misleading. The review apparently is not specific for oncology care. I would suggest the...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Ramucirumab Plus Docetaxel Improves Outcomes in Bladder Cancer

(Medscape Medical News) Mar 2, 2015 - Adding the new antiangiogenic agent ramucirumab (Cyramza, Eli Lilly and Company) to docetaxel (multiple brands) chemotherapy has shown promising results as a second-line therapy in advanced or metastatic urothelial carcinoma.
read article (free registration required) »

Novel Combination 'Encouraging' in Advanced Kidney Cancer

(Medscape Medical News) Mar 2, 2015 - An investigational antiangiogenic inhibitor of the ALK1 pathway and a VEGF inhibitor showed promising activity and a good safety profile in advanced renal cell carcinoma.
read article (free registration required) »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Genentech Distribution Shift for Cancer Meds Delays Patient Care: Survey (Wall Street Journal/Pharmalot blog)

In the name of better service to our patients, at least that is what our local drug rep said, we see that instead...posted by: Glenn Mills

Hospitals Mount Campaign Against Site-Neutral Medicare Payments (ModernHealthcare)

This report is somewhat misleading. The review apparently is not specific for oncology care. I would suggest the...posted by: Thomas Marsland, MD

A Biological Quest Leads to a New Kind of Breast Cancer Drug (NPR/Shots blog)

Yes ... at $118k for just one of the treatment components. The cost is an issue that needs to be addressed.posted by: Winston Wong, PharmD

Black Women Less Likely to Take Breast Cancer Hormone Therapy (Reuters Health)

While I understand that there is a 37% less likelihood that an African-American woman is compliant with their hormone...posted by: Winston Wong, PharmD

BlueCross, Tennessee Oncology Pilot Digital Tools to Improve Care, Experience For Cancer Patients (Morningstar)

I believe that this will be the first study that will show the impact of clinical pathways upon clinical outcomes....posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Bayer has posted 1 new job.

Check out the OBR Job Board here.

Sponsored Content


Colon Cancer Awareness

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers worldwide. Kantar Health's new interactive colorectal cancer (CRC) infographic highlights the unmatched global reach of oncology data from our best-in-class data sources. The infographic captures data from Japan, Germany, China, Brazil and the U.S. - a small sample of our global capabilities.

View Infographic >>




COA_AnnualConf_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
BLRX +15.63%
ADXS +8.58%
ONCY +8.41%
CERU -8.01%
MNKD -7.23%
APRI -5.53%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: March 8, 2015
Company: Novartis / Sandoz
Product: Zarxio™ (filgrastim, EP2006)

Date: March 2015
Company: Nektar Therapeutics
Product: NKTR-102

Date: Q1 2015
Company: Cell Therapeutics
Product: pacritinib

See All OBR Radar items»